Binimetinib

Also known as: MEK162, ARRY-162, ARRY-438162, Mektovi, MEK 162, ARRY 162, ARRY 438162, 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide, 6-(4-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide, 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethoxy)amide, QCR-138, cc-455

Binimetinib (CAS 606143-89-9) is a compound in the Organic Compounds category listed in the Jingsj chemical database. It has the molecular formula C17H15BrF2N4O3 and a molecular weight of 441.227 g/mol. Key property: a density of 1.67. No supplier offers are currently listed; request a quote. Record last updated Aug 21, 2026.

CAS No.: 606143-89-9
Jingsj CID: J-1957463-1
Molecular Formula: C₁₇H₁₅BrF₂N₄O₃
Molecular Weight: 441.227 g/mol
Category: Organic Compounds
Last updated: 8/21/2026

Request MSDS / TDS

No offers for this compound yet.

Request a quote

Physicochemical Properties

Density	1.67
Exact Mass	440.029541
PSA	91.90000
LogP	5.42
Refractive Index	1.652
Storage Conditions	-20℃

Activity & Biological Data

Target	MEK:12 nM (IC50) Autophagy
Additional Information	[1]. J Pheneger, et al. 2006, ACR Annual Scientific Meeting. Abst 794. [2]. Serra V, et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest, 2013, 123(6), 2551-2563. [3]. Kiessling MK, et al. Mutant HRAS as novel target for MEK and mTOR inhibitors. Oncotarget. 2015 Dec 8;6(39):42183-96. [4]. Cheng H, et al. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene. 2016 Jun 9;35(23):2961-70. [5]. Seip K, et al. Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. Oncotarget. 2016 Apr 12;7(15):19997-20015.

Target

MEK:12 nM (IC50) Autophagy

Additional Information

[1]. J Pheneger, et al. 2006, ACR Annual Scientific Meeting. Abst 794. [2]. Serra V, et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest, 2013, 123(6), 2551-2563. [3]. Kiessling MK, et al. Mutant HRAS as novel target for MEK and mTOR inhibitors. Oncotarget. 2015 Dec 8;6(39):42183-96. [4]. Cheng H, et al. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene. 2016 Jun 9;35(23):2961-70. [5]. Seip K, et al. Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. Oncotarget. 2016 Apr 12;7(15):19997-20015.

Frequently Asked Questions

What is the CAS number of Binimetinib?

The CAS number of Binimetinib is 606143-89-9.

What are the molecular formula and molecular weight of Binimetinib?

Binimetinib has molecular formula C17H15BrF2N4O3 and molecular weight 441.227 g/mol.

What are the upstream and downstream products of Binimetinib?

For Binimetinib, Upstream Products: Methyl 5-amino-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylate, 4-Bromo-2-fluoro-1-iodobenzene.

Data compiled from public chemical databases such as PubChem and supplier catalogs; supplier offers are provided by suppliers.

Last updated: 8/21/2026

How to cite: Jingsj. "Binimetinib (CAS 606143-89-9)". Jingsj Chemical Database. https://www.jingsj.com/compound/J-1957463-1 (accessed 2026-11-09).

Data for reference only; verify product details with suppliers before purchase.